Analyser av Devyser Diagnostics

Devyser Q2: Profitable from here on - Redeye

Redeye returns with a more in-depth take on the Q2 report.

Devyser Q2: Initial take – positive EBIT thanks to higher distributor sales - Redeye

Redeye leaves an initial comment on the strong Q2 report, where OPEX cuts and higher distributor sales (from Thermo Fisher) resulted in a po...

Redeye • 22 Jul 08:56

Devyser: Redeye Q2 2025e preview - Redeye

Redeye presents its preview for Devyser’s Q2 2025 report, due on July 22.

Redeye • 30 Jun 08:10

Devyser Q1: A most exciting year - Redeye

Redeye reiterates its base case following the company’s Q1 report.

Redeye • 30 Apr 10:04

Devyser: Redeye Q1 2025e preview - Redeye

Redeye presents its preview for Devyser’s Q1 2025 report, due on April 29.

Redeye • 22 Apr 14:21

Devyser Q4: Looking strong on corrected numbers - Redeye

Redeye returns with a more in-depth take on the Q4 report.

Redeye • 14 Feb 10:51

Devyser Q4: Initial take – good signs from Thermo Fisher partnership - Redeye

Redeye notes a substantial sales contribution from distributors, in which Thermo Fisher sales are recorded but lower-than-expected direct sa...

Redeye • 13 Feb 11:27

Devyser: Redeye Q4 2024e preview - Redeye

Redeye presents its preview for Devyser’s Q4 2024 report, due on February 13.

Redeye • 06 Feb 12:50

Devyser: CEO change and strong preliminary Q4 results - Redeye

Redeye is impressed by the strong preliminary Q4 results, demonstrating an EBIT breakeven several quarters ahead of our anticipation.

Redeye • 17 Jan 07:14

Devyser CMD: Informative and supportive of our thesis - Redeye

Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day.

Redeye • 26 Nov 2024 15:07

Devyser Q3: All eyes on Q4 - Redeye

Redeye returns with a more in-depth take on Devyser’s Q3 report.

Redeye • 31 Oct 2024 10:58

Devyser Q3: All eyes on Q4 - Redeye

Redeye returns with a more in-depth take on Devyser’s Q3 report.

Redeye • 31 Oct 2024 10:58

Devyser Q3: Initial take – sales not impressive, but just a bump in the road - Redeye

Redeye sees that the y/y sales are disappointing, but considering the comparable quarter and its accelerating sales prospects, we feel that ...

Redeye • 30 Oct 2024 10:20

Devyser: Redeye Q3 2024e preview - Redeye

Redeye presents its preview for Devyser’s Q3 2024 report, due on October 30.

Redeye • 11 Oct 2024 12:54

Devyser Diagnostics: Sticky business worthy of a premium - Redeye

Redeye positively reviews the Thermo Fisher deal’s potential and the company’s US sales outlook.

Redeye • 20 Sep 2024 08:09

Devyser Diagnostics Q2: Entering a potentially case altering phase - Redeye

Redeye sees Q2 sales in line with our forecast but higher costs, prompting us to lower our 2024e EBIT assumptions.

Redeye • 01 Aug 2024 12:45

Devyser Diagnostics Q2: Initial take – robust sales - Redeye

Redeye notes Q2 sales spot on our estimates, but an EBIT far from our expectations (though heavily impacted by transitory costs).

Redeye • 23 Jul 2024 10:57

Devyser Diagnostics: Q2 2024e preview - Redeye

Redeye presents its preview for Devyser Diagnostics’ Q2 2024 report, due on July 23.

Redeye • 04 Jul 2024 07:30

Devyser Diagnostics Q1: The recognition of Devyser begins - Redeye

Redeye sees a quarter well in line with our estimates, and we believe that the quarterly reports will push the share the remaining c30% to o...

Redeye • 10 May 2024 09:38

Devyser: Redeye Q1 preview - Redeye

Redeye presents its preview for Devyser’s Q1 2024 report, which is due on May 8.

Redeye • 02 May 2024 10:59

Devyser Diagnostics: Nya avtal ger en lockande långsiktig potential - Analysguiden

Devyser fortsätter leverera på sin tillväxtagenda och ingår nya avtal som adderar tydliga konkurrensfördelar.

Analysguiden • 23 Feb 2024 09:12

Devyser Diagnostics Q4: Better positioned than ever - Redeye

Redeye missed on sales and EBIT but was positively surprised by the strong gross margin.

Redeye • 21 Feb 2024 08:07

Devyser: Lågt värderat tillväxtbolag bryter mark i västerled - Analysguiden

Kvartalet bjöd på en rekordhög tillväxt och fortsatt tydlig trend mot lönsamhet.

Analysguiden • 15 Nov 2023 10:14

Devyser: Vägen mot lönsamhet allt tydligare - Penser

Q3-rapporten visar var skåpet ska stå Efter en aningen blek utveckling under Q2’23, så blev det leverans av högsta klass i det tredje kvarta...

Penser • 10 Nov 2023 11:09

Devyser Diagnostics Q3: High sales growth ahead of additional growth drivers - Redeye

Redeye embraces the strong sales growth in the quarter, and we emphasise the coming revenue growth drivers that should become more visible d...

Redeye • 10 Nov 2023 08:43

Devyser Diagnostics: Expanding the Thermo Fischer agreement - Redeye

Redeye is pleased to hear that Devyser’s agreement with diagnostics giant Thermo Fischer has been expanded to include Brazil.

Redeye • 06 Sep 2023 13:25

Devyser: Tillfälligt hack i tillväxtkurvan - Penser

Blandad kompott Utvecklingen under det andra kvartalet var försäljningsmässigt inte så starkt som vi hade hoppats på, medan vi överraskades ...

Penser • 29 Aug 2023 11:09

Devyser Diagnostics Q2: An unnoticed high-quality growth case - Redeye

Redeye is encouraged by the continuing geographical expansion, and that first sales have come from the Thermo Fischer deal (in Q3), but we m...

Redeye • 25 Aug 2023 15:27

Devyser: Laddar upp inför starkt H2 - Analysguiden

Devyser växte med 23% i Q2 och bruttomarginalen var fortsatt stark.

Analysguiden • 25 Aug 2023 09:51

Devyser: Ljusa framtidsutsikter - Penser

Bra inledning på 2023 Året har börjat minst sagt i en positiv anda.

Penser • 15 May 2023 11:35

Devyser Diagnostics Q1: Accelerating its operations for expansion - Redeye

Redeye notes a higher OPEX than expected in the company’s Q1 report.

Redeye • 11 May 2023 14:13

Devyser: Snabbväxande doldis som går under radarn - Analysguiden

Tillväxtresan fortsätter och Devyser växer organiskt med 22% i Q1.

Analysguiden • 10 May 2023 15:57

Devyser Diagnostics: Perfekt match med Thermo Fisher - Penser

Ideal partner inom transplantationsområdet Det exklusiva samarbets- och distributionsavtal med Thermo Fisher Scientific som bolaget annonser...

Penser • 25 Apr 2023 11:15

Devyser Diagnostics: Agreement with Thermo Fischer Scientific - Redeye

Redeye embraces Devyser’s agreement with Thermo Fisher regarding its post-transplantation monitoring products.

Redeye • 25 Apr 2023 09:24

Devyser: Ingår högintressant avtal - Analysguiden

Devyser har aviserat att de ingått ett exklusivt samarbetsavtal med Thermo Fischer Scientific.

Analysguiden • 24 Apr 2023 15:42

Devyser: Tillväxtcaset solitt - Penser

Bra tillväxt och höga investeringar Rapporten för det fjärde kvartalet visade åter prov på den höga tillväxt som bolaget kan leverera.

Penser • 27 Feb 2023 11:06

Devyser: Uppnår högt ställda mål & USA blir intressant 2023 - Analysguiden

Devyser lämnar ett starkt helår bakom sig och står välrustade inför ett högintressant 2023.

Analysguiden • 23 Feb 2023 09:45

Devyser Diagnostics Q4: A robust quarter for the overlooked high-performer - Redeye

Redeye is positive to Devyser’s Q4 report as the company continues to deliver well on its key metrics and demonstrates a progress in line wi...

Redeye • 22 Feb 2023 15:08

Devyser Diagnostics: Redeye Q4 2022e preview - Redeye

Redeye shares its preview of Devyser Diagnostics’ Q4 2022 results, due on February 21.

Redeye • 09 Feb 2023 12:37

Devyser: Lockande läge inför 2023 - Penser

Upplagt för bra avslutning på 2022 Devyser har fortsatt visa hög tillväxt under hela 2022.

Penser • 04 Dec 2022 11:10

Devyser: Stabilt kvartal och många pusselbitar faller på plats - Analysguiden

Devyser fortsätter att växa försäljningen i hög takt under Q3 och har aviserat ett flertal viktiga nyheter.

Analysguiden • 16 Nov 2022 07:44

Devyser Diagnostics Q3: Solid performance and strong gross margin - Redeye

Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight deviation in sales and OPEX compared to...

Redeye • 11 Nov 2022 07:38

Devyser: Tillväxt i sitt DNA - Penser

Tydlig tillväxtprofil Devyser är ett snabbväxande diagnostikbolag med ambitionen att bli en ledande aktör inom avancerad DNA-testning som ut...

Penser • 08 Nov 2022 11:04

Devyser Q2: Delivering well on its financial targets - Redeye

Redeye is once again positively surprised by the strong gross margin (80% Act.

Redeye • 29 Aug 2022 08:07

Devyser Diagnostics: Stark tillväxt och vinner viktig mark i Kanada - Analysguiden

Devyser levererar ett kvartal präglat av hög organisk tillväxt och tar ett viktigt kliv in på den Nordamerikanska marknaden.

Analysguiden • 26 Aug 2022 14:11

Devyser: Wins Breakthrough Contract in Canada - Redeye

Redeye is encouraged to learn that Devyser has been awarded a tender from Héma-Québec in Québec, Canada, for its non-invasive fetal RHD dete...

Redeye • 22 Jun 2022 13:49

Devyser Diagnostics: Snabbväxare inom gentest med skyhöga marginaler - Analysguiden

Analysguiden inleder bevakning av diagnostikbolaget Devyser med riktkurs 110 kronor.

Analysguiden • 07 Jun 2022 09:04

Devyser: A Strong Start to 2022 - Redeye

Redeye regards Devyser’s Q1’22 report as strong and was surprised by the high gross margin (83%), which came in 5 pp above our estimates and...

Redeye • 12 May 2022 08:49

Devyser: Next-Generation Diagnostics Company Put to the Test - Redeye

Redeye initiates coverage of Devyser, a rapidly growing Swedish diagnostics company that offers cutting-edge test kits in oncology, heredita...

Redeye • 06 Apr 2022 08:41